We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Catalyst Firdapse Gets Orphan Status for Myasthenia Gravis
Read MoreHide Full Article
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) announced that the FDA has granted orphan drug designation to Firdapse (amifampridine phosphate) for the treatment of myasthenia gravis.
Orphan drug designation is given to drugs being developed for rare diseases/disorders that affect less than 200,000 people in the U.S. Incentives that come with orphan drug status include close guidance from the FDA that may accelerate the time to marketing approval, orphan drug grants, tax credits and a period of market exclusivity upon marketing approval.
As per the information provided by the company, myasthenia gravis caused by antibodies to the muscle-specific kinase (MuSK-MG) is a rare disease, estimated to affect 5–8% of all myasthenia gravis patients, which means approximately 4,500 patients in the U.S.
The company is currently supporting an investigator-sponsored, randomized, double-blinded, placebo-controlled study evaluating Firdapse for the treatment of patients with MuSK-MG. Top-line results from this study are expected in early 2017.
Assuming positive results from the trial and availability of funds, Catalyst Pharma plans to initiate a registration quality trial in the U.S. to evaluate Firdapse in the treatment of MuSK-MG.
We remind investors that the FDA has granted Breakthrough Therapy Designation to Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Firdapse also enjoys orphan drug status for LEMS and congenital myasthenic syndromes (CMS) in the U.S. Moreover, the drug is approved in Europe for the symptomatic treatment of adults with LEMS.
Firdapse’s approval in the U.S. is critical to the company’s success. Earlier this year, the company received a refusal-to-file letter from the FDA in connection with its NDA for Firdapse. The agency had determined that the company’s NDA was insufficient after a preliminary review. Consequently, the company was required to conduct additional studies as per the agency’s requirements, which translated into additional costs.
Currently, Catalyst Pharma carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All of these stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Catalyst Firdapse Gets Orphan Status for Myasthenia Gravis
Catalyst Pharmaceuticals, Inc. (CPRX - Free Report) announced that the FDA has granted orphan drug designation to Firdapse (amifampridine phosphate) for the treatment of myasthenia gravis.
Orphan drug designation is given to drugs being developed for rare diseases/disorders that affect less than 200,000 people in the U.S. Incentives that come with orphan drug status include close guidance from the FDA that may accelerate the time to marketing approval, orphan drug grants, tax credits and a period of market exclusivity upon marketing approval.
As per the information provided by the company, myasthenia gravis caused by antibodies to the muscle-specific kinase (MuSK-MG) is a rare disease, estimated to affect 5–8% of all myasthenia gravis patients, which means approximately 4,500 patients in the U.S.
The company is currently supporting an investigator-sponsored, randomized, double-blinded, placebo-controlled study evaluating Firdapse for the treatment of patients with MuSK-MG. Top-line results from this study are expected in early 2017.
Assuming positive results from the trial and availability of funds, Catalyst Pharma plans to initiate a registration quality trial in the U.S. to evaluate Firdapse in the treatment of MuSK-MG.
We remind investors that the FDA has granted Breakthrough Therapy Designation to Firdapse for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Firdapse also enjoys orphan drug status for LEMS and congenital myasthenic syndromes (CMS) in the U.S. Moreover, the drug is approved in Europe for the symptomatic treatment of adults with LEMS.
CATALYST PHARMA Price
CATALYST PHARMA Price | CATALYST PHARMA Quote
Firdapse’s approval in the U.S. is critical to the company’s success. Earlier this year, the company received a refusal-to-file letter from the FDA in connection with its NDA for Firdapse. The agency had determined that the company’s NDA was insufficient after a preliminary review. Consequently, the company was required to conduct additional studies as per the agency’s requirements, which translated into additional costs.
Currently, Catalyst Pharma carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , Corcept Therapeutics Incorporated (CORT - Free Report) and ANI Pharmaceuticals, Inc. (ANIP - Free Report) . All of these stocks sport a Zacks Rank #1 (Strong Buy).
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>